Reconsidering the definition of a dose-volume histogram.

Physics in Medicine and Biology (Impact Factor: 2.7). 07/2005; 50(11):L17-19. DOI: 10.1088/0031-9155/50/11/L01
Source: PubMed

ABSTRACT The full text of this letter is given in the PDF file below.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Experimental evidence supports an association between heterogeneity in tumor perfusion and response to chemotherapy/radiotherapy, disease progression and malignancy. Therefore, changes in tumor perfusion may be used to assess early effects of tumor treatment. However, evaluating changes in tumor perfusion during treatment is complicated by extensive changes in tumor type, size, shape and appearance. Therefore, this study assesses the regional heterogeneity of tumors by dynamic contrast-enhanced MRI (DCE-MRI) and evaluates changes in response to isolated limb perfusion (ILP) with tumor necrosis factor alpha and melphalan. Data were acquired in an experimental cancer model, using a macromolecular contrast medium, albumin-(Gd-DTPA)45. Small fragments of BN 175 (a soft-tissue sarcoma) were implanted in eight brown Norway rats. MRI of five drug-treated and three sham-treated rats was performed at baseline and 1 h after ILP intervention. Properly co-registered baseline and follow-up DCE-MRI were used to estimate the volume transfer constant (K(trans) ) pharmacokinetic maps. The regional heterogeneity was estimated in 16 tumor sectors and presented in cumulative map-volume histograms. On average, ILP-treated tumors showed a decrease in regional heterogeneity on the histograms. This study shows that heterogenic changes in regional tumor perfusion, estimated using DCE-MRI pharmacokinetic maps, can be measured and used to assess the short-term effects of a potentially curative treatment on the tumor microvasculature in an experimental soft-tissue sarcoma model. Copyright © 2013 John Wiley & Sons, Ltd.
    Contrast Media & Molecular Imaging 07/2013; 8(4):340-9. · 2.87 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate incidental doses to benign lung tissue for patients with minimally moving lung lesions treated with respiratory gating. Seventeen lung patient plans were studied retrospectively. Tumor motion was less than 5 mm in all cases. For each patient, mid-ventilation (MidVen) and mid-inhalation (MidInh) breathing phases were reconstructed. The MidInh phase was centered on the end-of-inhale (EOI) phase within a 30% gating window. Planning target volumes, heart, and spinal cord were delineated on the MidVen phase and transferred to the MidInh phase. Lungs were contoured separately on each phase. Intensity-modulated radiotherapy plans were generated on the MidVen phases. The plans were transferred to the MidInh phase, and doses were recomputed. The evaluation metric was based on dose indices, volume indices, generalized equivalent uniform doses, and mass indices for targets and critical structures. Statistical tests were used to establish the significance of the differences between the reference (MidVen) and compared (MidInh) dose distributions. Statistical tests demonstrated that the indices evaluated for targets, cord, and heart differed by within 2.3%. The index differences in the lungs, however, are in excess of 6%, indicating the potentially achievable lung sparing and/or dose escalation. Respiratory gating is a clinical option for patients with minimally moving lung lesions treated at EOI. Gating will be more beneficial for larger tumors, since dose escalation in those cases will result in a larger increase in the tumor control probability.
    International journal of radiation oncology, biology, physics 05/2010; 77(1):285-91. · 4.59 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Currently, determination of body composition is the most useful method for distinguishing between certain diseases. The prompt-gamma in vivo neutron activation analysis (IVNAA) facility for non-destructive elemental analysis of the human body is the gold standard method for this type of analysis. In order to obtain accurate measurements using the IVNAA system, the activation probability in the body must be uniform. This can be difficult to achieve, as body shape and body composition affect the rate of activation. The aim of this study was to determine the optimum pre-moderator, in terms of material for attaining uniform activation probability with a CV value of about 10% and changing the collimator role to increase activation rate within the body. Such uniformity was obtained with a high thickness of paraffin pre-moderator, however, because of increasing secondary photon flux received by the detectors it was not an appropriate choice. Our final calculations indicated that using two paraffin slabs with a thickness of 3 cm as a pre-moderator, in the presence of 2 cm Bi on the collimator, achieves a satisfactory distribution of activation rate in the body.
    Journal of Radiation Research 02/2013; · 1.45 Impact Factor


Available from